Ex Vivo Systems: Patient-Derived, Patient-Specific Tumor Cultures

• 653 Rapid drug sensitivity testing of passage-zero patient brain tumor tissues to inform preclinical and clinical decisions: results from a clinical feasibility study Breanna Mann, Nichole Artz, Adebimpe Adefolaju, Alain Valdivia, Xiaopei Zhang, Rajaneekar Dasari, Caroline Stockwell, Morrent Thang, Allison Murray, Noah Bell, Andrew Buckley, Rami Darawsheh, Kerry Fitzgerald, Jonathan Williams, Hardik Parikh, Shuang Gao, Jie An, Yvette Rodriguez, Daniel Metzger, Collin Parrow, Dylan Riley, Robert Seager, Stephanie B. Hastings, Taylor Jensen, Shakti Ramkissoon, Dominique Higgins, Yasmeen Rauf, Scott Elton, Kimberly Hamilton, Jeremy Wang, Albert Baldwin, Shawn Hingtgen, David Kram, Andrew Satterlee
• 654 · PDF A modular positioning platform for standardized ex vivo specimen analysis in preclinical optical imaging Max Harlacher, Jeffrey D. Peterson, James Tseng, Jessica Pesner, Bincy John
• 655 · PDF Clinical validation of pembro response predictions from TNBC patient biopsies using E slices Kyuson Yun, Viridiana L. Leyva-Aranda, Claire Yun, Nourhan ABDELFATTAH, Clinton Yam, Fransisca Leonard, Reece Kang, Jangsoon Lee, Naoto Ueno
• 656 · PDF A patient-derived ex vivo platform for personalized evaluation of both direct and immune-mediated drug responses Jie Wen, Hao Cheng, Nan Yang
• 657 · PDF The era of NAMS, incorporating tumor heterogeneity and immune context into human-relevant patient avatar cancer models W. Gregory Sawyer, Ryan Smolchek, Duy Nguyen, Alfonso Pepe, Diego Pedro, Erin George, Roger Li
• 658 · PDF Establishment of a novel ex vivo bone metastasis culture platform for triple-negative breast cancer Tiina E. Kähkönen, Saif Wahid, Sangita Kushary, Debabani Roy Chowdhury, Arnab Roy Chowdhury, Jussi M. Halleen
• 659 Ex vivo evaluation of a MUC1-targeted bispecific T-cell engager in ovarian tumoroids using Nilogen's 3D-EXpress platform Vanessa Garrido, Janine DeBlasi, Andrea Mockabee, Seth Currlin, Justin Silberman, Jessica Linkous, Alliyah Humphrey, Jared Ehrhart
• 660 · PDF Integrating passage-zero patient tumor tissues from distant institutions into a rapid, ex vivo drug screening platform Adebimpe Adefolaju, Breanna Mann, Rajaneekar Dasari, Emma Livne, Caroline Stockwell, Alain Valdivia, Sonia Lipp, Angel Augst, Kerry Fitzgerald, Jonathan Williams, Hardik Parikh, Shuang Gao, Jie An, Taylor Jensen, Shakti Ramkissoon, Dominique Higgins, Yasmeen Rauf, Scott Elton, Kimberly Hamilton, Yair Gozal, Vincent DiNapoli, Albert Baldwin, Shawn Hingtgen, David Kram, Andrew Satterlee
• 661 Rapid CAR T testing in an ex vivo platform that maintains passage-zero patient tumor tissues and their native immunosuppressive microenvironment Xiaopei Zhang, Breanna Mann, Adebimpe Adefolaju, Alain Valdivia, Rajaneekar Dasari, Caroline Stockwell, Noah Bell, Ashley Geiger, Tracy A. Withers, Xin Zhou, Alexa Rodriguez, Kerry Fitzgerald, Jon Williams, Hardik Parikh, Shuang Gao, Jie An, Taylor Jensen, Shakti Ramkissoon, Dominique Higgins, Yasmeen Rauf, Scott Elton, Kimberly Hamilton, Albert Baldwin, Barbara Savoldo, Shawn Hingtgen, David Kram, Andrew Satterlee
• 662 Non-animal platforms using ex-vivo human tissue and live-cell biosensors enable functional drug testing in renal cell carcinoma Shuchi Gulati, Madhura Patankar, Elijah Kofke, Michael Pargett, Daniel Oberbauer, Ching-Hsien Chen, John G. Albeck
• 663 · PDF TOP1i-ADC demonstrates immune-stimulating activity in colorectal cancer explants Irene I. Lee, Durga B. Dandamudi, Yoshiko Hashikawa, Marion L. Refici, Michelle Belmont, Iraz Aydin, Rhyannon Spangler, Steven Chirieleison, David Sharon, PK Epling-Burnette, Athan Vasilopoulos, Tamar Uziel, Jack Chen, Lloyd Lam
• 664 · PDF Bulk cancer spheroid preservation and post-thaw viability for high-throughput screening applications Hilary Sherman, Rock Pulak
• 665 Bridging tumor heterogeneity and drug response: A patient-derived immune-competent 3D spheroid model for translational oncology Charlotte Veser, Zuzanna Kotkowska, Irina Agarkova, Sue Grepper, Madhu Nag-LAL, Laure-Anne Ligeon
• 666 · PDF Developing an ascitic fluid-derived organoid model for transcriptomic and therapeutic investigations in ovarian cancer Md Mynul Hassan, Zulfikar Azam, Taslim A. Al-Hilal, Sourav Roy
• 667 · PDF Mapping and targeting spatial heterogeneity in CRC through patient-derived organoids Maxim Norkin, Jonathan Bac, Louis McConnel, Sylvie Andre, Marina Alexandra Gaveta, Joerg Huelsken, Marianna Rapsomaniki, Raphael Gottardo, Krisztian Homicsko
• 668 Establishment of a patient-derived organoid-immune cell co-culture platform for evaluating the efficacy of immuno-oncology therapies Yuhui Wang, Pengyu Li, Chuyue Yu, Mingshuo Zhang, Pengwei Pan, Fang He
• 669 · PDF Development and characterization of a patient-derived liver organoid biobank for toxicology and functional studies Rudra Bhowmick, Benjamen O'Donnell, Fong Cheng Pan, Mahi Rahman, Sameena Wani, Willem Kools, Vi Chu
• 670 · PDF Understanding the role of the tumor suppressor gene ARID1A in gastric cancer initiation Alexa Morales Arana, Nicole Britney Halmai, Jasmine Diaz, Hongyong Zhang, Paul Lott, UCaMP consortium, UCaTS consortium, Luis Carvajal-Carmona
• 672 Mapping tumor heterogeneity: Ex-Vivo drug responses in synchronous matched primary and metastatic tumors using a 3D functional precision platform Rajeshwar Nitiyanandan, Ivan Trus, Chiara Maestri, Ricardo J. Parker, Chris Apfel
• 673 Longitudinal mapping of immune activation to tumor response in anti-PD1-treated patient-derived organotypic tumor spheroids (PDOTS) Jun Yang, Julia Vail, Eunju Shin, Kyungjin Boo, Kirti Khardenavis, Sinal Patel, Kyoung Wan Yoon, Michael A. Perricone
• 674 · PDF Expansion of multilineage prostate organoids derived from human tissue in ProstaCult™ organoid medium Angela Tsai, Allen C. Eaves, Sharon A. Louis, John Stingl
• 675 · PDF B7-H3 targeting ADC GSK5764227 demonstrates broad and varied anti-tumor activity across solid tumor translational models Michael Adam, Miriam Doepner, Ning Sun, Chris Hopson, Derek Poore, Prajna Behera, Jenny Laraio, Anthony Mazurek, Andrew Gehman, Shannon McKearnan, Jacob Parsons, Bjoern-Philipp Kloke, Shoba Shetty, Ken Hance, Jeremy Waight, Klaas Bakker
• 676 · PDF Modeling patient-specific therapeutic outcomes in cervical cancer using organoid technology Shalmoli Bhattacharyya, Surbhi Singla, Reena Sharma, Bhavana Rai, Rashmi Bagga, Radhika Srinivasan, Prateek Bhatia
• 677 · PDF Development of an in vitro exhaustion assay for functional screening of CAR T cell enhancements Carla N. Castro, Veronica Bergo, Marina Zintchenko, Susana Minguet, Philipp Metzger, Cynthia Obodozie, Holger Weber
• 679 · PDF BRAF-defined canine urothelial carcinoma organoids as a comparative oncology platform for drug response evaluation Kieun Bae, Kyong-Ah Yoon, Doyoung Jeon, Jimin Park, Aryung Nam, Jung-Hyun Kim, Hyun-Jung Han, Hun-Young Yoon
• 680 · PDF Clinically predictive patient-derived cells and organoids platforms for precision therapeutic evaluation in NSCLC Jiwoo Hwang, Min Hak Lee, Gang-Taik Lee, So Young Park, Byoung Chul Cho
• 681 · PDF C3PO: complex 3D patient organoids for preclinical drug testing in brain tumors Antonino Cucinotta, Maria Rosaria Battista, Francesco Scalabrì, Anastasiya Kraynyeva, Chiara Soldati, Cristina Alli, Carlo Toniatti, Alessandro Carugo, Francesca Puca

在完整检索应用中浏览本分会场 →